Abstract
Biological agents, such as multikinase inhibitors and mammalian target of rapamycin (mTOR) inhibitors, have replaced immunotherapy as the standard of care for metastatic renal cell carcinoma (mRCC). Several clinical trials have been performed, aimed to identify new feasible therapeutic targets. AKT, PI3K, STAT3, NOTCH-1, α5β1-integrin, CD70 and G250 are just examples of these opening frontiers. Novel agents, combination and sequences are emerging from the 887 clinical studies presently in course in mRCC to optimize patient outcomes. This report not includes studies on chemotherapy, local approaches, immunotherapy, surgical trials and other categories, but provides an update on ongoing phase I, II and III trials and preliminary results on targeted agents, used alone, in sequences or in combination for mRCC.
Keywords: Clinical trials, Combined targeted therapy, Novel targeted agents, Renal cell carcinoma, Sequential targeted therapy
Current Cancer Drug Targets
Title:Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?
Volume: 13 Issue: 3
Author(s): Matteo Santoni, Mimma Rizzo, Luciano Burattini, Rossana Berardi, Giacomo Carteni and Stefano Cascinu
Affiliation:
Keywords: Clinical trials, Combined targeted therapy, Novel targeted agents, Renal cell carcinoma, Sequential targeted therapy
Abstract: Biological agents, such as multikinase inhibitors and mammalian target of rapamycin (mTOR) inhibitors, have replaced immunotherapy as the standard of care for metastatic renal cell carcinoma (mRCC). Several clinical trials have been performed, aimed to identify new feasible therapeutic targets. AKT, PI3K, STAT3, NOTCH-1, α5β1-integrin, CD70 and G250 are just examples of these opening frontiers. Novel agents, combination and sequences are emerging from the 887 clinical studies presently in course in mRCC to optimize patient outcomes. This report not includes studies on chemotherapy, local approaches, immunotherapy, surgical trials and other categories, but provides an update on ongoing phase I, II and III trials and preliminary results on targeted agents, used alone, in sequences or in combination for mRCC.
Export Options
About this article
Cite this article as:
Santoni Matteo, Rizzo Mimma, Burattini Luciano, Berardi Rossana, Carteni Giacomo and Cascinu Stefano, Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?, Current Cancer Drug Targets 2013; 13 (3) . https://dx.doi.org/10.2174/1568009611313030009
DOI https://dx.doi.org/10.2174/1568009611313030009 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Carbonic Anhydrase Inhibitors and the Management of Cancer
Current Topics in Medicinal Chemistry Zinc and its Specific Transporters as Potential Targets in Airway Disease
Current Drug Targets Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery Monocarboxylate Transporter 1 in Brain Diseases and Cancers
Current Drug Metabolism Recent Developments of Platinum-based Anticancer Drugs- Detection and Analysis in Biological Samples
Current Organic Chemistry Cubilin, the Intrinsic Factor-Vitamin B12 Receptor in Development and Disease
Current Medicinal Chemistry Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Chemical and Radiochemical Considerations in Radiolabeling with α-Emitting Radionuclides
Current Radiopharmaceuticals HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design Modulatory Effects of Peroxisome Proliferator-Activated Receptor-γ on CXCR3 Chemokines
Recent Patents on Inflammation & Allergy Drug Discovery Bortezomib as an Antitumor Agent
Current Pharmaceutical Biotechnology Computational and Synthetic Biology Approaches for the Biosynthesis of Antiviral and Anticancer Terpenoids from <i>Bacillus subtilis</i>
Medicinal Chemistry Novel Therapeutic Approaches in Limiting Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tumor Specific Imaging Using Tc-99m and Ga-68 Labeled Radiopharmaceuticals
Current Medical Imaging Chronic Inflammation in the Pancreas and Salivary Glands - Lessons from Similarities and Differences in Pathophysiology and Treatment Modalities
Current Pharmaceutical Design PiWi RNA in Neurodevelopment and Neurodegenerative Disorders
Current Molecular Pharmacology Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer Treatment
Current Bioactive Compounds Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy
Current Drug Targets XMT-1001, A Novel Biodegradable Polyacetal Polymer Conjugate of Camptothecin in Clinical Development
Current Bioactive Compounds